Categories
Jump to navigation
Jump to search
The following categories exist on the wiki, and may or may not be unused. Also see wanted categories.
(first | last) View (previous 500 | next 500) (20 | 50 | 100 | 250 | 500)- 5 alpha-reductase inhibitors (2 members)
- ACVR1 inhibitors (1 member)
- AKT1 inhibitors (4 members)
- ALK inhibitors (9 members)
- AXL inhibitors (2 members)
- AbbVie product (1 member)
- Acid pump antagonists (1 member)
- Acquired coagulopathy medications (2 members)
- Acquired coagulopathy regimens (1 member)
- Acquired hemophilia A medications (7 members)
- Acquired hemophilia A regimens (1 member)
- Acquired thrombotic thrombocytopenic purpura medications (7 members)
- Acquired thrombotic thrombocytopenic purpura regimens (1 member)
- Acute leukemias (15 members)
- Acute lymphoblastic leukemia, infant medications (4 members)
- Acute lymphoblastic leukemia, infant regimens (2 members)
- Acute lymphoblastic leukemia medications (1 member)
- Acute lymphoblastic leukemia regimens (3 members)
- Acute lymphoblastic leukemias (10 members)
- Acute myeloid leukemia medications (40 members)
- Acute myeloid leukemia medications (historic) (11 members)
- Acute myeloid leukemia medications (investigational) (10 members)
- Acute myeloid leukemia regimens (9 members)
- Acute promyelocytic leukemia medications (16 members)
- Acute promyelocytic leukemia regimens (2 members)
- Adrenal suppressant (1 member)
- Adrenergic receptor agonists (1 member)
- Adrenocortical carcinoma medications (6 members)
- Adrenocortical carcinoma medications (investigational) (1 member)
- Adrenocortical carcinoma regimens (2 members)
- Adult T-cell leukemia-lymphoma medications (17 members)
- Adult T-cell leukemia-lymphoma regimens (2 members)
- Adult T-cell leukemia/lymphoma medications (0 members)
- Adult T-cell leukemia/lymphoma regimens (0 members)
- Aggressive lymphomas (7 members)
- Aggressive non-Hodgkin lymphomas (11 members)
- Alkalinization (1 member)
- Alkyl sulfonates (1 member)
- Alkylating agents (34 members)
- Allogeneic HSCT regimens (1 member)
- Alloimmune hematologic conditions (1 member)
- Alpha emitters (1 member)
- Alveolar soft part sarcoma medications (1 member)
- Alveolar soft part sarcoma regimens (1 member)
- Aminopeptidase inhibitor (1 member)
- Anabolic steroids (2 members)
- Anal cancer medications (11 members)
- Anal cancer regimens (1 member)
- Anaplastic glioma medications (16 members)
- Anaplastic glioma regimens (2 members)
- Anaplastic large cell lymphoma, pediatric medications (1 member)
- Anaplastic large cell lymphoma medications (14 members)
- Anaplastic large cell lymphoma regimens (2 members)
- Androgen receptor inhibitors (1 member)
- Angiosarcoma medications (3 members)
- Angiosarcoma regimens (1 member)
- Anthracenedione (1 member)
- Anthracyclines (12 members)
- Anti-BCMA-CD3 bispecific antibodies (2 members)
- Anti-BCMA/CD3 bispecific antibodies (0 members)
- Anti-BCMA CAR T-cells (2 members)
- Anti-BCMA antibodies (1 member)
- Anti-BCMA antibody-drug conjugates (1 member)
- Anti-BCMA bispecific T-cell engager antibodies (0 members)
- Anti-BCMA cellular therapy (2 members)
- Anti-C1s antibodies (1 member)
- Anti-C5 antibodies (4 members)
- Anti-CCR4 antibodies (1 member)
- Anti-CD137 cellular therapy (4 members)
- Anti-CD19-CD3 bispecific antibodies (1 member)
- Anti-CD194 antibodies (1 member)
- Anti-CD19 BiTE antibodies (0 members)
- Anti-CD19 CAR T-cells (4 members)
- Anti-CD19 antibodies (2 members)
- Anti-CD19 antibody-drug conjugates (3 members)
- Anti-CD19 bispecific T-cell engager antibodies (0 members)
- Anti-CD19 cellular therapy (4 members)
- Anti-CD20-CD3 bispecific antibodies (3 members)
- Anti-CD20 BiTE antibodies (0 members)
- Anti-CD20 antibodies (14 members)
- Anti-CD20 bispecific T-cell engager antibodies (0 members)
- Anti-CD20 cellular therapy (0 members)
- Anti-CD20 radioimmunoconjugates (2 members)
- Anti-CD22 antibodies (3 members)
- Anti-CD22 antibody-drug conjugates (1 member)
- Anti-CD22 immunotoxins (2 members)
- Anti-CD27 antibodies (1 member)
- Anti-CD28 cellular therapy (2 members)
- Anti-CD30 antibodies (1 member)
- Anti-CD30 antibody-drug conjugates (1 member)
- Anti-CD33-CD3 bispecific antibodies (1 member)
- Anti-CD33/CD3 bispecific antibodies (0 members)
- Anti-CD33 antibodies (2 members)
- Anti-CD33 antibody-drug conjugates (2 members)
- Anti-CD33 bispecific T-cell engager antibodies (0 members)
- Anti-CD33 radioimmunoconjugates (1 member)
- Anti-CD37 antibodies (1 member)
- Anti-CD37 medications (0 members)
- Anti-CD38 antibodies (5 members)
- Anti-CD3 antibodies (0 members)
- Anti-CD3 cellular therapy (4 members)
- Anti-CD47 antibodies (1 member)
- Anti-CD52 antibodies (1 member)
- Anti-CD79B antibodies (1 member)
- Anti-CD79B antibody-drug conjugates (1 member)
- Anti-CD7 CAR T-cells (1 member)
- Anti-CLDN18.2 antibodies (1 member)
- Anti-CTLA-4 antibodies (2 members)
- Anti-DKK1 antibodies (1 member)
- Anti-DLL3-CD3 bispecific antibodies (1 member)
- Anti-EGFR-HGFR bispecific antibodies (1 member)
- Anti-EGFR/HGFR bispecific antibodies (0 members)
- Anti-EGFR antibodies (3 members)
- Anti-EGFRvIII CAR T-cells (2 members)
- Anti-EpCAM-CD3 bispecific antibodies (1 member)
- Anti-EpCAM BiTE antibodies (0 members)
- Anti-EpCAM antibodies (1 member)
- Anti-EpCAM bispecific T-cell engager antibodies (0 members)
- Anti-FOLR1 antibodies (1 member)
- Anti-FOLR1 antibody-drug conjugates (1 member)
- Anti-Factor IXa-Factor Xa bispecific antibodies (1 member)
- Anti-Factor IXa antibodies (0 members)
- Anti-Factor XIa antibodies (1 member)
- Anti-Factor Xa antibodies (0 members)
- Anti-GD2 CAR T-cells (1 member)
- Anti-GD2 antibodies (3 members)
- Anti-GD2 cellular therapy (1 member)
- Anti-GP-3 antibodies (1 member)
- Anti-GPIIb-IIIa antibodies (1 member)
- Anti-GPRC5D-CD3 bispecific antibodies (1 member)
- Anti-GPRC5D/CD3 bispecific antibodies (0 members)
- Anti-GPRC5D CAR T-cells (1 member)
- Anti-GPRC5D antibodies (0 members)
- Anti-GPRC5D bispecific T-cell engager antibodies (0 members)
- Anti-GPRC5D cellular therapy (1 member)
- Anti-HER2 antibodies (13 members)
- Anti-HER2 antibody-drug conjugates (2 members)
- Anti-HGFR antibodies (0 members)
- Anti-HGF antibodies (1 member)
- Anti-IFNg antibodies (1 member)
- Anti-IGF-1R antibodies (3 members)
- Anti-IL-2R immunotoxins (1 member)
- Anti-IL-5 antibodies (2 members)
- Anti-IL-6R antibodies (1 member)
- Anti-IL-6 antibodies (1 member)
- Anti-IL3 immunotoxins (0 members)
- Anti-KIR antibodies (1 member)
- Anti-LAG-3 antibodies (1 member)
- Anti-MAGE-A4 SPEAR T-cells (1 member)
- Anti-NGcGM3 antibodies (1 member)
- Anti-P-selectin antibodies (1 member)
- Anti-PD-1 antibodies (14 members)
- Anti-PD-L1 antibodies (6 members)
- Anti-PDGFR antibodies (1 member)
- Anti-PS antibodies (1 member)
- Anti-RANKL antibodies (1 member)
- Anti-SLAMF7 antibodies (1 member)
- Anti-TACSTD2 antibodies (1 member)
- Anti-TACSTD2 antibody-drug conjugates (1 member)
- Anti-TFPI antibodies (1 member)
- Anti-TF antibodies (1 member)
- Anti-TF antibody-drug conjugates (1 member)
- Anti-TRAIL-R1 antibodies (1 member)
- Anti-TRAIL-R2 antibodies (1 member)
- Anti-VEGFR antibodies (1 member)
- Anti-VEGF antibodies (8 members)
- Anti-amyloid antibodies (1 member)
- Anti-c-Met antibodies (1 member)
- Anti-dabigatran antibody fragments (1 member)
- Anti-diarrheals (1 member)
- Anti-mesothelin antibodies (1 member)
- Anti-nectin-4 antibodies (1 member)
- Anti-nectin-4 antibody-drug conjugates (1 member)
- Anti-vWF medications (1 member)
- Antiandrogens (7 members)
- Antibacterials (10 members)
- Antibiotics (4 members)
- Antibody-drug conjugates (11 members)
- Antibody medications (6 members)
- Anticoagulant reversal agents (2 members)
- Anticoagulants (20 members)
- Anticoagulation factors (1 member)
- Antiestrogens (4 members)
- Antifolates (8 members)
- Antifungals (7 members)
- Antihelminthic (1 member)
- Antihistamines (8 members)
- Antileukotrienes (1 member)
- Antimetabolites (25 members)
- Antineoplastic bispecific antibodies (1 member)
- Antineoplastic monoclonal antibodies (41 members)
- Antineoplastics by class effect (5 members)
- Antiparasitic (1 member)
- Antiphospholipid antibody syndrome medications (2 members)
- Antiphospholipid antibody syndrome regimens (1 member)
- Antiplatelet agents (5 members)
- Antipsychotic (2 members)
- Antipyretics (5 members)
- Antithymocyte globulin (3 members)
- Antitumor antibiotics (7 members)
- Antivirals (4 members)
- Aplastic anemia medications (7 members)
- Aplastic anemia regimens (1 member)
- Apoptosis promoters (2 members)
- Appendiceal tumor regimens (1 member)
- Appetite stimulants (2 members)
- Approved drugs (6 members)
- Aromatase inhibitors (3 members)
- Aromatase inhibitors, first generation (1 member)
- Aromatase inhibitors, second generation (2 members)
- Aromatase inhibitors, third generation (3 members)
- Arsenic compound (3 members)
- Asparagine-specific enzymes (5 members)
- AstraZeneca product (2 members)
- Atypical hemolytic uremic syndrome medications (4 members)
- Atypical hemolytic uremic syndrome regimens (1 member)
- Aurora kinase inhibitors (2 members)
- Autoimmune cytopenia medications (2 members)
- Autoimmune cytopenia regimens (1 member)
- Autoimmune hematologic conditions (7 members)
- Autoimmune hemolytic anemia regimens (0 members)
- Autologous HSCT regimens (1 member)
- B-cell acute lymphoblastic leukemia medications (42 members)
- B-cell acute lymphoblastic leukemia medications (historic) (4 members)
- B-cell acute lymphoblastic leukemia medications (investigational) (1 member)
- B-cell acute lymphoblastic leukemia regimens (6 members)
- B-cell lymphoma medications (6 members)
- B-cell lymphoma regimens (11 members)
- B-cell lymphomas (18 members)
- BRAF inhibitors (7 members)
- BRAF medications (0 members)
- BRAF regimens (0 members)
- BTK inhibitors (8 members)
- Bcl-2 inhibitors (1 member)
- Bcl-2 translation inhibitors (1 member)
- Bcr-Abl inhibitors (9 members)
- Benzodiazepine (3 members)
- Beta emitters (1 member)
- Beta thalassemia medications (2 members)
- Beta thalassemia regimens (1 member)
- Biliary tract cancer regimens (0 members)
- Biliary tract cancers (5 members)
- Biologic products (3 members)
- Biomarker-specific medications (2 members)
- Biomarker-specific pages (53 members)
- Biosimilars (33 members)
- Bispecific antibody medications (3 members)
- Bisphosphonates (6 members)
- Bladder cancer medications (21 members)
- Bladder cancer medications (historic) (0 members)
- Bladder cancer medications (investigational) (0 members)
- Bladder cancer regimens (3 members)
- Blastic plasmacytoid dendritic cell neoplasm medications (1 member)
- Blastic plasmacytoid dendritic cell neoplasm regimens (1 member)
- Bleeding disorders (4 members)
- Bone marrow failure syndromes (5 members)
- Bone protective medications (2 members)
- Bone sarcoma medications (3 members)
- Bone sarcoma regimens (4 members)
- Bone sarcomas (11 members)
- Bowel management (2 members)
- Breast cancer medications (70 members)
- Breast cancer medications (historic) (21 members)
- Breast cancer medications (investigational) (5 members)
- Breast cancer pages (2 members)
- Breast cancer regimens (15 members)
- Bristol-Myers Squibb product (2 members)
- Burkitt lymphoma medications (17 members)
- Burkitt lymphoma regimens (1 member)
- CDK4 inhibitors (4 members)
- CDK6 inhibitors (4 members)
- CDK inhibitors (4 members)
- CFDA approved drugs (0 members)
- CK1 epsilon inhibitors (1 member)
- CK1 inhibitors (1 member)
- CNS cancers (8 members)
- CNS carcinoma medications (0 members)
- CNS carcinoma regimens (1 member)
- CNS hemangioblastoma medications (1 member)
- CNS leukemia medications (5 members)
- CNS leukemia regimens (1 member)
- CNS lymphoma medications (27 members)
- CNS lymphoma regimens (2 members)
- CNS melanoma regimens (1 member)
- COX-1 inhibitors (4 members)
- COX-2 inhibitors (2 members)
- CSF1R inhibitors (5 members)
- CXCR4 inhibitors (2 members)
- CYP17 inhibitors (5 members)
- Calcineurin inhibitors (2 members)
- Cannabinoid (2 members)
- Carbonic anhydrase inhibitors (1 member)
- Carcinoma of unknown primary medications (16 members)
- Carcinoma of unknown primary regimens (1 member)
- Castleman disease medications (12 members)
- Castleman disease regimens (1 member)
- Cellular therapy (13 members)
- Cellular therapy regimens (1 member)
- Cephalosporin (2 members)
- Cephalotaxine (1 member)
- Cereblon E3 ubiquitin ligase modulators (1 member)
- Cervical cancer medications (26 members)
- Cervical cancer regimens (3 members)
- Chelators (5 members)
- Chemotherapy protective agents (12 members)
- Chimeric antigen receptor T-cells (6 members)
- Cholangiocarcinoma medications (27 members)
- Cholangiocarcinoma regimens (2 members)
- Chronic lymphocytic leukemia medications (34 members)
- Chronic lymphocytic leukemia medications (historic) (5 members)
- Chronic lymphocytic leukemia medications (investigational) (4 members)
- Chronic lymphocytic leukemia regimens (2 members)
- Chronic myelogenous leukemia medications (historic) (0 members)
- Chronic myelogenous leukemia medications (investigational) (0 members)
- Chronic myelogenous leukemia regimens (0 members)
- Chronic myeloid leukemia medications (20 members)
- Chronic myeloid leukemia medications (historic) (3 members)
- Chronic myeloid leukemia medications (investigational) (0 members)
- Chronic myeloid leukemia regimens (3 members)
- Chronic myelomonocytic leukemia medications (5 members)
- Chronic myelomonocytic leukemia regimens (1 member)
- Classical Hodgkin lymphoma medications (44 members)
- Classical Hodgkin lymphoma medications (historic) (8 members)
- Classical Hodgkin lymphoma medications (investigational) (1 member)
- Classical Hodgkin lymphoma regimens (5 members)
- Classical hematologic conditions (7 members)
- Classical hematology medications (23 members)
- Classical hematology regimens (18 members)
- Clear cell renal cell carcinoma medications (10 members)
- Clear cell renal cell carcinoma regimens (2 members)
- Clinical pharmacology (16 members)
- Clusterin inhibitor (1 member)
- Coagulation factors (11 members)
- Coagulopathy medications (1 member)
- Coagulopathy regimens (4 members)
- Cold agglutinin disease medications (11 members)
- Cold agglutinin disease medications (investigational) (0 members)
- Cold agglutinin disease regimens (1 member)
- Colon cancer medications (9 members)
- Colon cancer medications (historic) (6 members)
- Colon cancer medications (investigational) (1 member)
- Colon cancer regimens (8 members)
- Colorectal cancer medications (46 members)
- Colorectal cancer medications (historic) (1 member)
- Colorectal cancer medications (investigational) (0 members)
- Colorectal cancer regimens (6 members)
- Colorectal cancers (10 members)
- Combination drugs (8 members)
- Complement factor D inhibitors (1 member)
- Complement pathway inhibitors (2 members)
- Complementopathies (3 members)
- Complementopathy medications (3 members)
- Complementopathy regimens (3 members)
- Condition (3 members)
- Craniopharyngioma medications (2 members)
- Craniopharyngioma regimens (1 member)
- Cross-disciplinary conditions (4 members)
- Cutaneous T-cell lymphoma medications (15 members)
- Cutaneous T-cell lymphoma medications (investigational) (1 member)
- Cutaneous T-cell lymphoma regimens (2 members)
- Cutaneous basal cell carcinoma medications (7 members)
- Cutaneous basal cell carcinoma regimens (1 member)
- Cutaneous lymphomas (2 members)
- Cutaneous squamous cell carcinoma medications (8 members)
- Cutaneous squamous cell carcinoma regimens (2 members)
- Cytokines (2 members)
- Cytopenias (6 members)
- Cytotoxic T-cells (1 member)
- Cytotoxic chemotherapeutic (17 members)
- DDR inhibitors (1 member)
- DNA methyltransferase inhibitors (5 members)
- Dendritic cell vaccines (1 member)
- Deoxycytidine analogs (3 members)
- Deoxycytidine analogues (0 members)
- Dermatofibrosarcoma protuberans medications (1 member)
- Dermatofibrosarcoma protuberans regimens (1 member)
- Desmoid tumor medications (8 members)
- Desmoid tumor medications (investigational) (0 members)
- Desmoid tumor regimens (2 members)
- Devices (1 member)
- Diffuse large B-cell lymphoma medications (62 members)
- Diffuse large B-cell lymphoma medications (historic) (8 members)
- Diffuse large B-cell lymphoma medications (investigational) (3 members)
- Diffuse large B-cell lymphoma regimens (3 members)
- Direct oral anticoagulants (5 members)
- Direct thrombin inhibitors (4 members)
- Discontinued drugs (37 members)
- Disease-specific pages (271 members)
- Diuretics (1 member)
- Dopamine receptor antagonist (6 members)
- Drug manufacturers (10 members)
- Drugs (778 members)
- Drugs by local effect (4 members)
- Drugs by vehicle (3 members)
- EGFR inhibitors (18 members)
- EGFR medications (0 members)
- EGFR regimens (0 members)
- EMA approved drugs (60 members)
- EMA approved in 1952 (1 member)
- EMA approved in 1953 (1 member)
- EMA approved in 1955 (1 member)
- EMA approved in 1956 (2 members)
- EMA approved in 1957 (1 member)
- EMA approved in 1958 (2 members)
- EMA approved in 1959 (3 members)
- EMA approved in 1962 (2 members)
- EMA approved in 1963 (2 members)
- EMA approved in 1966 (4 members)
- EMA approved in 1967 (1 member)
- EMA approved in 1970 (1 member)
- EMA approved in 1971 (2 members)
- EMA approved in 1974 (2 members)
- EMA approved in 1976 (3 members)
- EMA approved in 1977 (1 member)
- EMA approved in 1978 (2 members)
- EMA approved in 1979 (2 members)
- EMA approved in 1980 (2 members)
- EMA approved in 1981 (2 members)
- EMA approved in 1982 (5 members)
- EMA approved in 1984 (3 members)
- EMA approved in 1986 (3 members)
- EMA approved in 1987 (1 member)
- EMA approved in 1988 (1 member)
- EMA approved in 1989 (4 members)
- EMA approved in 1991 (1 member)
- EMA approved in 1992 (2 members)
- EMA approved in 1993 (2 members)
- EMA approved in 1994 (2 members)
- EMA approved in 1995 (9 members)
- EMA approved in 1996 (8 members)
- EMA approved in 1997 (1 member)
- EMA approved in 1998 (5 members)
- EMA approved in 1999 (1 member)
- EMA approved in 2000 (2 members)
- EMA approved in 2001 (9 members)
- EMA approved in 2002 (3 members)
- EMA approved in 2003 (2 members)
- EMA approved in 2004 (6 members)
- EMA approved in 2005 (3 members)
- EMA approved in 2006 (4 members)
- EMA approved in 2007 (7 members)
- EMA approved in 2008 (8 members)
- EMA approved in 2009 (9 members)
- EMA approved in 2010 (7 members)
- EMA approved in 2011 (6 members)
- EMA approved in 2012 (8 members)
- EMA approved in 2013 (15 members)
- EMA approved in 2014 (8 members)
- EMA approved in 2015 (12 members)
- EMA approved in 2016 (11 members)
- EMA approved in 2017 (14 members)
- EMA approved in 2018 (12 members)
- EMA approved in 2019 (13 members)
- EMA approved in 2020 (15 members)
- EMA approved in 2021 (18 members)
- EMA approved in 2022 (18 members)
- EMA approved in 2023 (12 members)
- EMA approved in 2024 (1 member)
- EMA withdrawn in 2012 (1 member)
- EMA withdrawn in 2013 (1 member)
- EMA withdrawn in 2015 (1 member)
- EMA withdrawn in 2017 (2 members)
- EMA withdrawn in 2018 (1 member)
- EMA withdrawn in 2019 (2 members)
- EMA withdrawn in 2020 (1 member)
- EMA withdrawn in 2021 (2 members)
- ERBB2 (HER2) medications (0 members)
- ERBB2 (HER2) regimens (0 members)
- ERBB2 inhibitors (6 members)
- ERBB3 (HER3) medications (0 members)
- ERBB3 (HER3) regimens (0 members)
- ERBB3 inhibitors (1 member)
- ERBB4 inhibitors (3 members)
- EZH1 inhibitors (1 member)
- EZH2 inhibitors (2 members)
- Emesis prevention (34 members)
- Endocrine cancers (15 members)
- Endocrine oncology medications (4 members)
- Endocrine oncology regimens (1 member)
- Endocrine therapeutic (16 members)
- Endometrial cancer medications (25 members)
- Endometrial cancer regimens (2 members)
- Enediyne antibiotic (2 members)
- Enzyme activator (1 member)
- Enzyme inhibitors (14 members)
- Enzymes (1 member)
- Epithelioid sarcoma medications (1 member)
- Epithelioid sarcoma regimens (1 member)
- Epothilones (1 member)
- Erdheim-Chester disease medications (4 members)
- Erdheim-Chester disease regimens (1 member)
- Erythrocyte growth factors (5 members)
- Esophageal adenocarcinoma medications (18 members)
- Esophageal cancer medications (41 members)
- Esophageal cancer medications (investigational) (0 members)
- Esophageal cancer regimens (6 members)
- Esophageal cancers (1 member)
- Esophageal squamous cell carcinoma medications (18 members)
- Esophageal squamous cell carcinoma medications (investigational) (0 members)
- Essential thrombocythemia medications (6 members)